Drug General Information
Drug ID	D0TR4Z
Former ID	DIB005864
Drug Name	Zindoxifene
Synonyms	D-16726
Drug Type	Small molecular drug
Indication	Breast cancer [ICD9: 174, 175; ICD10:C50]		Terminated	[544757]
Company	Evonik Degussa GmbH
Structure		Download 2D MOL 3D MOL
Formula	C21H21NO4
Canonical SMILES	n1(c(c(c2c1ccc(c2)OC(=O)C)C)c1ccc(OC(=O)C)cc1)CC
CAS Number	CAS 86111-26-4
PubChem Compound ID	65645
Target and Pathway
Target(s)	Estrogen receptor	Target Info	Modulator	[544032]
KEGG Pathway	Estrogen signaling pathway
	Prolactin signaling pathway
	Thyroid hormone signaling pathway
	Endocrine and other factor-regulated calcium reabsorption
	Proteoglycans in cancer
NetPath Pathway	FSH Signaling Pathway
	EGFR1 Signaling Pathway
	RANKL Signaling Pathway
Pathway Interaction Database	Regulation of nuclear SMAD2/3 signaling
	Signaling events mediated by HDAC Class II
	Plasma membrane estrogen receptor signaling
	LKB1 signaling events
	Regulation of Telomerase
	ATF-2 transcription factor network
	AP-1 transcription factor network
	FOXM1 transcription factor network
	Validated nuclear estrogen receptor alpha network
	Signaling mediated by p38-alpha and p38-beta
	FOXA1 transcription factor network
Reactome	Nuclear signaling by ERBB4
	Nuclear Receptor transcription pathway
WikiPathways	Estrogen signaling pathway
	Nuclear Receptors Meta-Pathway
	Estrogen Receptor Pathway
	Signaling by ERBB4
	JAK/STAT
	Integrated Pancreatic Cancer Pathway
	Leptin signaling pathway
	miR-targeted genes in muscle cell - TarBase
	Integrated Breast Cancer Pathway
	Nuclear Receptors
References
Ref 544757	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000885)
Ref 544032	Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.. Br J Cancer. 1990 March; 61(3): 451-453.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.